- Home
- PCAR vs ARGX Comparison
PCAR vs ARGX Comparison
Compare PCAR & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCAR
- ARGX
- Stock Information
- Founded
- PCAR 1905
- ARGX 2008
- Country
- PCAR United States
- ARGX Netherlands
- Employees
- PCAR N/A
- ARGX N/A
- Industry
- PCAR Auto Manufacturing
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCAR Consumer Discretionary
- ARGX Health Care
- Exchange
- PCAR Nasdaq
- ARGX Nasdaq
- Market Cap
- PCAR 47.0B
- ARGX 40.4B
- IPO Year
- PCAR N/A
- ARGX 2017
- Fundamental
- Price
- PCAR $88.17
- ARGX $596.20
- Analyst Decision
- PCAR Buy
- ARGX Strong Buy
- Analyst Count
- PCAR 12
- ARGX 20
- Target Price
- PCAR $111.41
- ARGX $699.56
- AVG Volume (30 Days)
- PCAR 3.7M
- ARGX 465.0K
- Earning Date
- PCAR 04-29-2025
- ARGX 05-08-2025
- Dividend Yield
- PCAR 4.46%
- ARGX N/A
- EPS Growth
- PCAR N/A
- ARGX N/A
- EPS
- PCAR 7.90
- ARGX 12.78
- Revenue
- PCAR $33,663,800,000.00
- ARGX $2,248,205,000.00
- Revenue This Year
- PCAR N/A
- ARGX $57.86
- Revenue Next Year
- PCAR $10.85
- ARGX $31.90
- P/E Ratio
- PCAR $11.16
- ARGX $43.64
- Revenue Growth
- PCAR N/A
- ARGX 77.22
- 52 Week Low
- PCAR $85.10
- ARGX $352.77
- 52 Week High
- PCAR $118.81
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- PCAR 38.26
- ARGX 51.80
- Support Level
- PCAR $86.25
- ARGX $583.00
- Resistance Level
- PCAR $91.01
- ARGX $610.06
- Average True Range (ATR)
- PCAR 4.04
- ARGX 24.42
- MACD
- PCAR -0.24
- ARGX 4.74
- Stochastic Oscillator
- PCAR 21.70
- ARGX 84.66
About PCAR PACCAR Inc.
Paccar is a leading manufacturer of medium- and heavy-duty trucks under the premium brands Kenworth and Peterbilt (primarily sold in the NAFTA region and Australia), and DAF trucks (sold in Europe and South America). The company's trucks are sold through more than 2,300 independent dealers globally. Paccar Financial Services provides retail and wholesale financing for customers and dealers, respectively. The company commands roughly 30% of the Class 8 market share in North America and 17% of the heavy-duty market share in Europe.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.